Physicians at the University of Cincinnati are conducting a seven-year trial to test a cholesterol drug for the prevention of recurring colorectal cancer in patients who have been surgically treated.
The trial, funded by the National Surgical and Adjuvant Bowel and Breast Project, will study whether patients who have had CRC surgically removed can take statins to prevent polyp formation, thereby preventing a recurrence of CRC.
Over five years, the study will compare the effects of the cholesterol-lowering rosuvastatin (Crestor) to a placebo through regular exams and tests. In the last two years, physicians will actively follow -up to monitor CRC recurrence.
Read the release on University of Cincinnati trial.
Read more coverage on colorectal cancer:
- Study: 4% Increase in Hospitals Offering Computed Tomographic Colonography
- AHRQ Highlights Successful Strategies for Increasing CRC Screening, Infection Prevention
- Baylor Health, Eureka Form Alliance for Colorectal Cancer Research
The trial, funded by the National Surgical and Adjuvant Bowel and Breast Project, will study whether patients who have had CRC surgically removed can take statins to prevent polyp formation, thereby preventing a recurrence of CRC.
Over five years, the study will compare the effects of the cholesterol-lowering rosuvastatin (Crestor) to a placebo through regular exams and tests. In the last two years, physicians will actively follow -up to monitor CRC recurrence.
Read the release on University of Cincinnati trial.
Read more coverage on colorectal cancer:
- Study: 4% Increase in Hospitals Offering Computed Tomographic Colonography
- AHRQ Highlights Successful Strategies for Increasing CRC Screening, Infection Prevention
- Baylor Health, Eureka Form Alliance for Colorectal Cancer Research